Yifei Zhang1, Chunxiu Hu2, Jie Hong1, Jun Zeng2, Shenghan Lai3, Ankang Lv1, Qing Su4, Yan Dong4, Zhiguang Zhou5, Weili Tang5, Jiajun Zhao6, Lianqun Cui6, Dajin Zou7, Dawang Wang8, Hong Li9, Chao Liu10, Guoting Wu11, Jie Shen12, Dalong Zhu13, Weiqing Wang1, Weifeng Shen1, Guang Ning14, Guowang Xu15. 1. Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China. 2. Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China. 3. Johns Hopkins School of Medicine, Baltimore, MD. 4. Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China. 5. Second Xiangya Hospital of Central South University, Changsha, China. 6. Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. 7. Chang Hai Hospital, Second Military Medical University, Shanghai, China. 8. First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China. 9. Sir Run Run Shaw Hospital, Zhejiang Province, China. 10. Jiangsu Province Hospital, Jiangsu Province, China. 11. Shanghai Tenth People's Hospital of Tongji University, Shanghai, China. 12. Nanfang Hospital, Guangdong Province, China. 13. Nanjin Drum Tower Hospital, Jiangsu Province, China. 14. Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China guangning@medmail.com.cn xugw@dicp.ac.cn. 15. Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China guangning@medmail.com.cn xugw@dicp.ac.cn.
Abstract
OBJECTIVE: We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabetic patients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study. RESEARCH DESIGN AND METHODS: Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients inmetformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration). RESULTS: A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species compared with glipizide, especially at the 2- and 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P < 0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P < 0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend in metformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal. CONCLUSIONS: Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.
RCT Entities:
OBJECTIVE: We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabeticpatients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study. RESEARCH DESIGN AND METHODS: Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients in metformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration). RESULTS: A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species compared with glipizide, especially at the 2- and 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P < 0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P < 0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend in metformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal. CONCLUSIONS: Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.
Authors: J Wang; D Yan; A Zhao; X Hou; X Zheng; P Chen; Y Bao; W Jia; C Hu; Z-L Zhang; W Jia Journal: Osteoporos Int Date: 2019-02-18 Impact factor: 4.507